ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
120.63M
Enterprise Value 3
43.64M
Trailing P/E
N/A
Forward P/E 1
-2.78
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
1,402.67
Price/Book (mrq)
1.42
Enterprise Value/Revenue 3
507.50
Enterprise Value/EBITDA 6
-1.42

Trading Information

Stock Price History

Beta (5Y Monthly) 4.57
52-Week Change 33.78%
S&P500 52-Week Change 320.98%
52 Week High 316.47
52 Week Low 34.46
50-Day Moving Average 35.77
200-Day Moving Average 38.24

Share Statistics

Avg Vol (3 month) 3565.13k
Avg Vol (10 day) 3473.08k
Shares Outstanding 523.2M
Float 21.04M
% Held by Insiders 112.52%
% Held by Institutions 147.78%
Shares Short (Dec 30, 2019) 45.93M
Short Ratio (Dec 30, 2019) 410.05
Short % of Float (Dec 30, 2019) 429.04%
Short % of Shares Outstanding (Dec 30, 2019) 425.56%
Shares Short (prior month Nov 28, 2019) 45.04M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-35,988.20%

Management Effectiveness

Return on Assets (ttm)-23.13%
Return on Equity (ttm)-40.35%

Income Statement

Revenue (ttm)86k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)86k
EBITDA -30.83M
Net Income Avi to Common (ttm)-30.02M
Diluted EPS (ttm)-1.46
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)77.55M
Total Cash Per Share (mrq)3.35
Total Debt (mrq)159.27k
Total Debt/Equity (mrq)0.19
Current Ratio (mrq)10.08
Book Value Per Share (mrq)3.67

Cash Flow Statement

Operating Cash Flow (ttm)-33.56M
Levered Free Cash Flow (ttm)-23.24M